Ads
related to: Treatment Pah- Treatment Information
Consider This Option as Part
Of Your Treatment Algorithm.
- Identifying PAH Patients
See Patient Profiles To Understand
When To Consider This Treatment.
- Dosing & Administration
Review Dosing & Administration
Info To Start Treatment.
- PAH Basics
Get Resources to Help Assess
And Monitor PAH Adult Patients.
- Diagnostic Resources
Resources To Help You Diagnose,
Assess & Treat Your Patients.
- Insights from PAH Experts
See What 3 PAH Experts Discuss
Treatment Strategies.
- Treatment Information
Search results
Systemic juvenile arthritis: Symptoms, health effects, and more
Medical News Today· 1 day agoSystemic juvenile idiopathic arthritis (SJIA), or “Still’s disease,” is a rare autoinflammatory...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 6 days agoThe biotech stock is also well above its 50-day and 200-day moving averages. Halozyme is also a Tech...
New drug tested offers room to breathe for patients with deadly lung disease
WCVB Boston· 3 days agoThe U.S. Food and Drug Administration recently approved a breakthrough treatment, which was tested...
Mitsubishi UFJ Asset Management Co. Ltd. Has $1.90 Million Stock Position in Liquidia Co....
ETF DAILY NEWS· 5 hours agoMitsubishi UFJ Asset Management Co. Ltd. lowered its position in shares of Liquidia Co. (NASDAQ:LQDA – Free Report) by 14.2% in the fourth quarter, according to its most recent 13F filing with ...
Breakthrough treatment for people struggling to breathe
WCVB Boston· 3 days agoINSTEAD, HE’S MOVED FROM ONE MEDICATION TO ANOTHER OVER THE PAST 25 YEARS, ALWAYS PUSHING TO BE PART...
Earnings call: Liquidia Corporation eyes FDA nod for YUTREPIA By Investing.com
Investing.com· 7 days agoLiquidia Corporation (LQDA) reported its financial results for the first quarter of 2024 and...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 17 hours agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
GuruFocus.com via Yahoo Finance· 6 days agoHe mentioned that YUTREPIA's ability to offer a more flexible and durable treatment option positions it well to capture a significant portion of the oral market, which has ...
Inhibikase Therapeutics Inc (IKT) Q1 2024 Earnings Call Transcri
Guru Focus· 4 days agoThe company had positive interactions with FDA divisions, advancing regulatory discussions for its IKCO and Pro programs, potentially positioning these assets for opportunities in pulmonary ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoBOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson
Ads
related to: Treatment Pah